Carnegie`s Generic Liothyronine Sodium Receives Approval in the U.S.
Enforcement Report - Week of December 20, 2023
Sun Pharma, Lupin recall drugs in US on manufacturing woes
Enforcement Report - Week of November 8, 2023
ALTURiX acquires UK rights to Liothyronine
Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 meg, 25 meg, and 50 meg (US RLD: Cytomel Tablets).
Enforcement Report - Week of September 23, 2020
Acella Pharmaceuticals, LLC is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level. The products are being recalled because testing has found these lots to be sub potent. The product may have as low as 87% of the labeled amount of levothyroxine (T4). More information can be found at www.npthyroid.com/product-updates
Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid®
Bioiberica, a provider of identification, extraction and development of animal-derived active pharmaceutical ingredients (APIs), has launched its natural thyroid API for the treatment of hypothyroidism. Replacing or supplementing the hormones that are ineffectively produced by the human thyroid gland, the API specifically targets patients who prefer a natural origin treatment or those who continue to experience symptoms despite using the standard synthetic therapy.